Updated:
Inovio Pharmaceuticals
Inovio Pharmaceuticals is a asset manager based in Plymouth Meeting; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Inovio Pharmaceuticals
INOVIO is advancing novel immunotherapy technologies to reshape the future of treating and preventing infectious diseases and cancer.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Plymouth Meeting
Corporate office
Plymouth Meeting, PA, United States
Additional offices
San Diego, CA, United States
Principals
Jacqueline Shea
President & Chief Executive Officer
Laurent Humeau
Chief Scientific Officer
Peter Kies
Chief Financial Officer
Michael Sumner
Chief Medical Officer & Head of Development
Steve Egge
Chief Commercial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Inovio Pharmaceuticals?
Jacqueline Shea, Ph.D., is President and CEO, leading corporate strategy and investment allocation. The executive team includes Chief Scientific Officer Laurent Humeau, Chief Medical Officer Michael Sumner, and CFO Peter Kies. No external investment committee is disclosed.
How does Inovio Pharmaceuticals source proprietary deal flow?
Inovio develops its pipeline internally via its DNA medicine platform and proprietary CELLECTRA® delivery devices. Business development is handled by an internal team (per the firm's website contact page). No external deal flow networks are specified.
What investment stages does Inovio Pharmaceuticals typically target?
Inovio is a clinical-stage company; its pipeline ranges from discovery through late-stage clinical development. The lead candidate INO-3107 is under FDA BLA review, approaching potential commercialization. The firm also pursues partnerships for earlier-stage candidates.
Which sectors does Inovio Pharmaceuticals explicitly avoid?
Inovio does not publicly state specific sectors it avoids. Its focus is DNA-based immunotherapies and vaccines for oncology and infectious diseases, with no disclosed activity in gene editing or RNA-based therapies.
Does Inovio Pharmaceuticals maintain philanthropic structures?
The firm's website does not mention a foundation or philanthropic arm. All disclosed activities are R&D and clinical development for its DNA medicine platform.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: